For how we live.
The PROPOSITIS trial put babies on high-flow oxygen face-down or on their backs. Escalation of care was 15% versus 21% — a difference that did not reach significance, and the authors call the study inconclusive.
The SMART trial tested clesrovimab against palivizumab in premature and heart- and lung-affected infants. It was built to show safety, not to prove one prevents more RSV than the other.
A Buenos Aires surveillance cohort estimates 80.8% effectiveness against RSV hospitalisation in infants under three months — close to what the licensing trial found, in a real programme.